Together, the trials confirm a class effect of SGLT2 inhibition in reducing heart failure hospitalizations across the left ventricle ejection fraction (LVEF) continuum, though modest or non-significant effects on mortality persist, emphasizing the need for ongoing mechanistic and comparative studies. This evidence concerns the gene SLC5A2 and heart failure.